{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-007981","form_type":"8-K","ticker":"NUS","cik":"0001021561","company_name":"NU SKIN ENTERPRISES, INC.","filed_at":"2024-02-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.130987+00:00","generated_at":"2026-06-06T01:55:09.975410+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Nu Skin Q4 rev $488.6M (-6%), adj EPS $0.37; CSO departs; FY guide $1.73-1.87B","bullets":["Q4 revenue $488.6M (-6% YoY), adj EPS $0.37 vs $0.89; reported EPS $0.15.","FY2023 revenue $1.97B (-12%); adj EPS $1.85 after inventory write-off charges.","FY2024 guidance: rev $1.73-1.87B, adj EPS $0.95-1.35; Q1 rev $400-435M, adj EPS $0.00-0.10.","Quarterly dividend set at $0.06/share; record Feb 26, payable Mar 6, 2024.","CSO Joseph Chang departs Mar 30; will transition to Scientific Advisory Board; role no longer executive."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-007981","json":"https://secwatch.observer/filing/0001140361-24-007981.json","markdown":"https://secwatch.observer/filing/0001140361-24-007981.md","text":"https://secwatch.observer/filing/0001140361-24-007981.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1021561/000114036124007981/0001140361-24-007981-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1021561/000114036124007981/ef20021676_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T01:55:09.975410+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"198bb5abb9911825491f25ac34564eb895481d2f","claim":"NU SKIN ENTERPRISES, INC. reported Full-year 2024 results: revenue $1.73 to $1.87 billion, EPS $0.75 to $1.15 or $0.95 to $1.35 non-GAAP. Guidance reaffirmed.","evidence_excerpt":"2024 Revenue $1.73 to $1.87 billion; (12)% to (5)% • Approximately (1)% FX impact 2024 EPS $0.75 to $1.15 or $0.95 to $1.35 non-GAAP","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1021561/000114036124007981/0001140361-24-007981-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Full-year 2024"},{"label":"Revenue","value":"$1.73 to $1.87 billion"},{"label":"EPS","value":"$0.75 to $1.15 or $0.95 to $1.35 non-GAAP"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"88047cf7530d74494e819a0e3b66fc8ed8761922","claim":"NU SKIN ENTERPRISES, INC. reported Q1 2024 results: revenue $400 to $435 million, EPS $(0.07) to $0.03. Guidance reaffirmed.","evidence_excerpt":"Q1 2024 Revenue $400 to $435 million; (17)% to (10)% • Approximately (3) to (2)% FX impact Q1 2024 EPS $(0.07) to $0.03 or $0.00 to $0.10 non-GAAP","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1021561/000114036124007981/0001140361-24-007981-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Q1 2024"},{"label":"Revenue","value":"$400 to $435 million"},{"label":"EPS","value":"$(0.07) to $0.03"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"bb1d4aee82c37f4236410d79e00f1ead68f30f13","claim":"NU SKIN ENTERPRISES, INC. reported financial results for the three-month and annual periods ended December 31, 2023.","evidence_excerpt":"On February 14, 2024, Nu Skin Enterprises, Inc. (the “Company”) issued a press release announcing its financial results for the three-month and annual periods ended December 31, 2023, and certain other information.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1021561/000114036124007981/0001140361-24-007981-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three-month and annual periods ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"2467a976d1","claim":"Joseph Chang departed as Chief Scientific Officer at NU SKIN ENTERPRISES, INC..","evidence_excerpt":"Joseph Chang informed Nu Skin Enterprises, Inc. (the “Company”) that he will be stepping down from his role as Chief Scientific Officer as of March 30, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1021561/000114036124007981/0001140361-24-007981-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"stepping down"},{"label":"Role","value":"Chief Scientific Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}